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INTRODUCTION
Recent increased concerns about breast cancer have resulted 
in a rise in the number of breast screening methods and have 
affected the diagnosis and treatment of early breast cancer. The 
detection rate of abnormal masses is higher with ultrasonog-
raphy (USG) than with mammography because Korean wom-
en tend to have denser breasts than Western women. Further-
more, with current technical advances and accumulated user’s 
experience, USG is becoming an increasingly important tool 
to diagnose breast diseases. As a result, there are debates on 
how to treat the mass lesions found on USG.  
Sonographically visible solid masses can be characterized 
according to the Breast Imaging Reporting and Data System 
(BI-RADS) ultrasound lexicon [1]. USG criteria used to define 
a probable benign solid breast mass, i.e., BI-RADS category 3, 
are its oval shape, circumscribed margins, parallel orientation 
to the chest wall, abrupt interface between the mass and the 
surrounding tissue, hypo- or isoechogenicity, increased or un-
changed posterior echoes, and no change in the surrounding 
tissue. All of these criteria are required to assess a probable be-
nign mass on USG. 
When a non-palpable breast lesion detected on screening 
mammography or USG is categorized as probable benign, the 
standard practice is to perform a 6-month follow-up mammog-
raphy or USG for 2 years [2]. Such lesions have a <2% risk of be-
ing cancerous. Even if such lesions are actually malignant, they 
can be diagnosed when patients are still asymptomatic by detect-
ing changes during follow-up [2,3]. Although it is appropriate 
to monitor any changes in a breast lesion for 1 to 3 years, pa-
tients may wander from hospital to hospital having doubt or 
unnecessary anxiety or forget to revisit the hospital for follow-
up whether or not advanced breast cancer has developed dur-
ing later years. Therefore, a selective histological diagnosis is 
necessary to assure patients and to obviate a misdiagnosis for 
lesions higher than BI-RADS category 2. 
Many controversies exist over the management of palpable 
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The gold standard for breast biopsy procedures is currently an 
open excision of the suspected lesion. However, an excisional 
biopsy inevitably makes a scar. The cost and morbidity associat-
ed with this procedure has prompted many physicians to evalu-
ate less invasive, alternative procedures. More recently, image-
guided percutaneous core-needle biopsy has become a frequent-
ly used method for diagnosing palpable and non-palpable breast 
lesions. Although sensitivity rates for core-needle biopsy are high, 
it has the disadvantage of histological underestimation, which 
renders the management of atypical ductal hyperplasia, papillary 
lesions, and fibroepithelial lesions somewhat difficult. Vacuum 
assisted breast biopsy (VABB) was developed to overcome some 
of these negative aspects of core-needle biopsy. VABB allows for 
a sufficient specimen to be obtained with a single insertion and 
can provide a more accurate diagnosis and completely remove 
the lesion under real-time ultrasonic guidance. The advantage of 
complete lesion removal with VABB is to reduce or eliminate sam-
pling error, to decrease the likelihood of a histological underesti-
mation, to decrease imaging-histological discordance, to decrease 
the re-biopsy rate, and to diminish the likelihood of subsequent 
growth on follow-up. In recent years, with the advancement of 
VABB instruments and techniques, many outcome studies have 
reported on the use of VABB for resecting benign breast lesions 
with a curative intent. VABB is highly accurate for diagnosing sus-
picious breast lesions and is highly successful at treating pre-
sumed benign breast lesions. Thus, in the near future, VABB will 
be routinely offered to all appropriately selected patients. 
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lesions. Biopsy is usually recommended, even if the lesion appears 
as probable benign morphology on imaging [1,3], as there are 
relatively few data supporting the outcome of such cases [4,5].
Many studies have reported that triple tests for discriminat-
ing benign and malignant lesions have an accuracy rate of 95%, 
but these methods are imperfect [6]. If a palpable mass with 
benign morphology is malignant, the follow-up may be riskier 
than that of a non-palpable lesion. The risk for metastasis is 
higher if tissue confirmation is delayed, as palpable masses are 
usually larger than non-palpable lesions. Furthermore, benign-
appearing malignant lesions tend to be high-grade invasive 
carcinomas, which usually grow rapidly [7].
Currently, the gold standard for breast biopsy procedures is 
open excision of the suspected lesion. However, an excisional 
biopsy inevitably leaves a scar. The cost and morbidity associat-
ed with this procedure has prompted many physicians to eval-
uate less invasive, alternative procedures [8-10]. The goal of min-
imally invasive biopsy procedures is to limit the physical im-
pact of biopsies by reducing the invasiveness of the procedure 
and to reduce procedural costs without sacrificing accuracy.
Fine-needle aspiration (FNA) biopsy has been proposed as 
a less invasive, cost-effective alternative and has been adopted 
at several institutions. However, this method has not been wide-
ly accepted, primarily because of a high non-diagnostic rate of 
up to 40% [11,12]. This rate is mostly related to cytological sam-
ples with insufficient material for diagnosis. Non-diagnostic 
results cause unnecessary delays in diagnosis, the necessity for 
repeat biopsies, and increased costs.
More recently, image-guided percutaneous core-needle bi-
opsy has become a frequently used method to diagnose palpa-
ble and non-palpable breast lesions. Although sensitivity rates 
for 14-gauge automated-needle biopsy are high (97%), some 
cancers are missed. Another shortcoming is that disease sever-
ity is sometimes underestimated, i.e., when surgical excision 
findings show a higher degree of pathology than that at the 
previous breast biopsy [13]. A carcinoma finding after a biopsy 
diagnosis of atypical ductal hyperplasia (ADH) or of invasive 
carcinoma after a biopsy diagnosis of ductal carcinoma in situ 
(DCIS), defines ADH- and DCIS-underestimates, respective-
ly. Not only is it psychologically distressing for patients when 
breast cancer is underestimated, but it also implies a delay in 
establishing a definitive diagnosis, hence, appropriate treatment. 
Many of these patients will need additional surgical procedures. 
Difficulties in histological diagnosis using core-needle biop-
sies stem largely from the limited amount of material available 
in a core and uncertainties over whether the sample is repre-
sentative. In an attempt to overcome some of these negative 
aspects of core-needle biopsy, vacuum assisted breast biopsy 
(VABB) was developed at the end of 1995 [14]. VABB allows 
the operator to obtain a sufficient amount of specimen with a 
single insertion to provide for a more accurate diagnosis and 
can aid in completely removing the lesion with the guidance 
of real time USG [15,16]. 
The advantage of complete lesion removal with VABB is to 
reduce or eliminate sampling error, to decrease the likelihood 
of histological underestimation, to decrease the imaging-his-
tological discordance, to decrease the re-biopsy rate, and to 
diminish the likelihood of subsequent growth on follow-up. 
With advancement in VABB instruments and techniques, many 
trials have been conducted to remove benign lesions with a 
curative intent [17-19]. However, VABB has many advantages 
but is relatively costly. We have been developing practical clin-
ical guidelines for the indications of VABB. The objective of 
this review is to report the proper indications for VABB. 
INDICATIONS FOR VACUUM ASSISTED  
BREAST BIOPSY
Diagnostic indications
The main indications for VABB are palpable or non-palpa-
ble ACR classification BI-RADS category 3 and small 4A nod-
ular lesions. We usually follow-up in 3 to 6 months for benign-
looking lesions (BI-RADS category 3). However, according to 
the ability of each radiologist, the possibility of malignancy is 
variable but <3%. We recommend VABB excision instead of 
a core-needle biopsy if patients want a complete excision. The 
criteria we follow are: 1) patients with a low probability of reg-
ular follow-up, 2) patients who are planning to get pregnant, 
3) extremely restless patients, 4) patients with a lesion that is 
increasing in size during the follow-up, 5) patients who have 
subjective symptoms or pain with BI-RADS categories 3 to 4 
lesions [20].
Lesions smaller than 5 mm, mainly small stellate lesions, can 
sometimes be difficult to remove with a standard core biopsy. 
VABB provides a more certain histological result, because al-
most the entire lesion is retrieved. 
Some invasive lobular carcinomas do not present as nodules 
because of the infiltration pattern and are, therefore, missed 
on mammography. Nevertheless, this can extend over a large 
area. Broad sampling is recommended in these cases to pro-
vide an adequate histological diagnosis.
Only broad histological sampling allows for correctly distin-
guishing the histology between fibrocystic changes, atypia, and 
in situ carcinoma. A solitary complex cystic area in an other-
wise normal breast parenchyma must be considered suspicious 
and should be biopsied or removed by VABB if possible.
Small solitary papillomas can be accurately diagnosed with 
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phy is needed less often. The typical presentation is that of a 
small solid mass in a dilated duct or a highly vascularized cyst 
with low-resistance flow. It is more likely to find a papilloma 
close to the nipple area. If there is suspicion of a papilloma, 
which is a benign disease in the majority of cases, the lesion 
can be biopsied and removed using VABB. However, a papil-
loma is a lesion with an uncertain biological behavior, and it 
may be difficult to distinguish from intraductal carcinoma. A 
papilloma can become a papillary carcinoma over time. Area 
of DCIS can sometimes give a similar image on USG. Thus, 
removing these lesions is recommended, and surgery (micro-
dochectomy) is difficult and requires good preoperative local-
ization. VABB is a valuable alternative and has become the first 
choice for solitary papillomas [21,22].
Many microcalcification clusters are now visible on USG 
with improved US equipment. When the calcifications are sur-
rounded by hypoechoic solid tissue, as in DCIS, they are easi-
er to see. In difficult locations, in which the stereotactic proce-
dure is hazardous due to the lack of real time guidance, such 
as close to the skin, the pectoral muscle, or the axillary region, 
USG guidance offers a reliable and secure alternative because 
of real-time monitoring.
Compared to a standard core biopsy, the absence of a forward 
throw of the needle reduces the risk of touching sensitive struc-
tures; therefore, we recommend the use of VABB for lesions 
close to the nipple, the thoracic wall, the skin, or the axillary 
region. With experience, the retrieval of adequate samples from 
these lesions in these difficult locations is perfectly feasible.
Good histological results are obtained with VABB due to 
vacuum aspiration and the rotating cutter, even in the hardest 
lesions, where adequate core sampling fails.
VABB can be used in cases of inadequate FNAC or core-nee-
dle biopsy results. The literature reports false-negative results 
ranging from 8 to 15% for core-needle biopsy, much higher 
figures for FNA, and certainly with microcalcifications [8,9]. 
A more confident diagnosis can be obtained with VABB be-
cause of the larger volume of tissue obtained.
Therapeutic indications
Recently, the FDA approved use of the device for the thera-
peutic purpose of benign lesions [23,24]. Breast lesions, certain-
ly when they are palpable, cause a great deal of uncertainty and 
anxiety for the patient. Inconclusive radiological or clinical re-
ports aggravate these conditions, and a strong family history 
of cancer is also an aggravating factor. Many times, at the pa-
tient’s request, the decision is made to surgically remove a le-
sion that looks benign on imaging. VABB can be a better and 
less expensive alternative for lesion removal in these situations. 
Recently, lesions up to 2.5-3 cm were completely removed with 
minimal or no scarring [25-29]. The use of an 8-gauge needle 
is recommended for nodules 1 cm or larger. The lesion must 
be removed as completely as possible to prevent regrowth. 
Therefore, careful USG monitoring of the procedure is man-
datory. Extra samples should be obtained in different direc-
tions to be sure that the lesion is completely removed. 
Many outcome studies have been conducted on the use of 
VABB for resecting a fibroadenoma. Fine et al. [30] evaluated 
the safety, efficacy, and patient acceptance of using a 8- and 11- 
gauge VABB to percutaneously remove breast masses under US 
guidance. In a multicenter, nonrandomized study, 124 women 
with low-risk palpable lesions were evaluated. Complete remov-
al of the imaged lesion was excellent (99% 8-gauge vs. 96% 11- 
gauge). Complications were minimal, and the patient satisfac-
tion rate was 97%, and 98% of the patients would recommend 
the procedure to others.
Johnson et al. [23] hypothesized that the complete removal of 
small benign lesions under US guidance in an outpatient set-
ting could be obtained with minimal morbidity using VABB. 
Eighty-one patients had 101 lesions excised. The average size 
of the lesions was 1.15±0.43 cm (range, 0.5-2.0 cm). Ninety-
four lesions (93%) had benign pathology, five lesions (5%) were 
malignant, and two (2%) lesions had atypical hyperplasia. They 
found that using VABB under US guidance is an effective tech-
nique to therapeutically manage benign lesions. Baez et al. [20] 
evaluated complete excision of benign breast tumors using US-
guided VABB. Twenty consecutive patients with sonographi-
cally benign breast lesions underwent three-dimensional (3D) 
US-guided VABB under local anesthesia, and the size of the 
lesion was assessed preoperatively using 2D and 3D volume-
try. The excisional biopsy was considered complete when no 
residual tumor tissue could be seen sonographically. US follow-
up examinations were performed on the following day and 3-6 
months later to assess residual tissue and scarring. The patient 
satisfaction rate was excellent, and no incidence of bleeding or 
wound infection was recorded. They concluded that US-guided 
VABB allows for the complete excision of benign breast lesions 
that are 1.5 mL in volume; thus avoiding open surgery and post-
operative scarring. This is a safe procedure with optimal com-
pliance under local anesthesia.
VABB can be used to determine whether leaving the nipple is 
safe in women requesting a nipple-conserving mastectomy for 
invasive or in situ disease. The needle is positioned beneath the 
nipple, and biopsy specimens are taken in a 360° direction [31].
We have performed over 5,700 procedures in nearly 10 years 
of using VABB. Among these cases, 5.0% (285 cases) were ma-
lignancies, and 95.0% were benign, which eliminated the need 
for short-term follow-up. According to the USG BIRADS clas-
sification, 65% were classified as category 3, and 34% were cat-4  Hai-LinPark,etal.
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egory 4A lesions. Of the category 3 lesions, 0.9% were proved 
to be malignant, and 14% of the category 4A lesions were ma-
lignant [27]. 
LIMITATIONS
Histological underestimates
Atypical ductal hyperplasia (ADH) is a lesion with some but 
not all of the features of DCIS but involves only one duct, or a 
lesion that has all of the features of DCIS but measures <2 mm. 
Therefore, the potential exists that a small sample of a DCIS 
lesion may be interpreted by the pathologist as ADH. Further-
more, some lesions may contain both ADH and DCIS, or DCIS 
and infiltrating carcinoma. The histological underestimation 
in such cases may simply result from sampling error.
ADH is found in approximately 5% of all breast biopsies with 
mammographic calcifications. Underestimate rates in the range 
of 18% to 88% have been reported for the stereotactic biopsy 
technique [32-34]. Stereotactic ADH underestimation rates are 
inversely correlated with the amount of tissue excised [35-37].
VABB diminishes the histological underestimation rates, 
compared to core-needle biopsy, because VABB produces 
heavier and larger specimens with more contiguous sampling 
and a higher retrieval rate of calcification. Liberman et al. [38]
demonstrated an increase from 4% complete lesion removal 
with automated core biopsy to 13% with VABB. Burbank [39]
similarly reported complete removal of 48% of lesions diag-
nosed by VABB compared with 15% of lesions removed by 
large-core needle biopsy.
Despite these higher reported accuracy rates, mammograph-
ic lesions that contain ADH during stereotactic VABB still have 
ADH underestimate rates sufficient to mandate open surgical 
excision for a diagnosis [35-37]. Other benign conditions, in-
cluding papillomatosis, radial scars, and lobular neoplasia also 
require an open excision.
Data are sparse regarding the underestimation of US-guid-
ed, vacuum-assisted biopsy. Grady et al. [16] conducted a study 
to ascertain accurate underestimation rates for US-guided VABB 
and to determine if these rates could be lowered significantly 
by removing all imaged lesion evidence. They reported that 
their ADH underestimate rate for completely excised lesions 
was zero, which was essentially equivalent to open surgical bi-
opsy. Given that a complete excision produces larger tissue 
samples for pathological study, this technique may be more 
accurate than traditional sonographic biopsy, as evidenced by 
lower ADH underestimation rates.
Epithelial displacement
Benign or malignant epithelium may be displaced into tissue 
away from the target lesion during a variety of breast needling 
procedures, including FNA, core biopsy, directional VABB, 
local anesthetic injection, and suture placement [40]. Epithelial 
displacement can cause interpretive problems for the patholo-
gist, as displaced DCIS can mimic infiltrating ductal carcino-
ma. A misdiagnosis of invasive carcinoma could lead to inap-
propriate therapy (i.e., axillary surgery or chemotherapy).
The largest study to address the epithelial displacement issue 
of large-core needle breast biopsies was conducted by Diaz et al. 
[40]. In 352 surgical excision specimens from women with a 
prior diagnosis of cancer by large-core needle biopsy, Diaz et 
al. [40] found displacement of malignant epithelium in 32% of 
cases. The frequency of tumor displacement is 37% after auto-
mated gun biopsy, 38% after palpation-guided biopsy, and 23% 
after VABB. Epithelial displacement may be less frequent after 
VABB than after automated core biopsy [41].
We hypothesize that firing the needle through the carcinoma 
is the step during the biopsy procedure most likely to result in 
displacement of malignant epithelium. At least five needle 
passes are made for masses during a core-needle biopsy, and 
often ten or more for calcifications. For each pass, the needle 
must traverse the carcinoma to obtain diagnostic material, be-
cause tissue is acquired only along the line of fire [42,43]. 
When the directional VABB probe is fired into the breast, it 
is usually fired only once, and it may be fired adjacent to rath-
er than through the lesion [44].
There are other possible explanations for the lower frequency 
of epithelial displacement during VABB than during core-nee-
dle biopsy. VABB acquires larger, more contiguous samples and 
facilitates obtaining a greater number of specimens. Because of 
the larger volume of tissue removed with the directional VABB 
probe, displaced cells are more likely to be retrieved. Further-
more, the use of vacuum may tend to draw cells (including 
those from outside the line of fire) into the probe rather than 
displace them from the biopsy cavity. Few data have addressed 
the biological significance of epithelial displacement. Berg et 
al. [45] and Robbins et al. [46] found no difference in the 15-
year survival rate in a study of stage-matched palpable invasive 
breast cancers treated by mastectomy after diagnosis by aspi-
ration biopsy or open biopsy. Although no evidence exists to 
date that displaced carcinomatous epithelium remains viable 
and grows in the breast, there may be a theoretical risk for local 
recurrence if that needling tract is not excised or administered 
radiotherapy. Further studies with a long-term follow-up in 
women treated with breast-conserving therapy after VABB are 
needed.
Incomplete excision
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nographic assistance, with the clinical endpoint being the re-
moval of all imaged evidence of the lesion as well as any evi-
dence of a palpable mass. Fine et al. [30] reported that 97% of 
women demonstrated complete removal of the imaged mass 
immediately after biopsy. Of the women with data available at 
6 months after biopsy, repeat sonography showed that 73% still 
had no sonographic evidence of the initially diagnosed mass. 
However 27% had a residual mass at the 6-month follow-up 
sonography. They suggested several possibilities for why a re-
sidual mass was seen at 6 months in 27% of patients, which 
included the following: space orientation is not so good under 
2D USG guidance, due to the effect of local anesthesia, which 
may blur the operative field and contribute to a visual challenge 
when the tumor gets smaller during the procedure, as well as 
procedural bleeding; the mass was not completely removed 
and enlarged over the ensuing months; or the 6-month changes 
were due to post-biopsy scarring or fibrosis. 
The rate of successful initial complete removal of a lesion 
varies widely from 22 to 100%, although most studies report 
rates of 75-100%. Follow-up rates without recurrence are 62-
98% [28,30,47-51].
These variations may, in part, be explained by the use of dif-
ferently gauged devices (ranging from 8-14 gauge), different 
methods for assessing the completeness of removal (including 
clinical, radiological, and histological), and a the range of his-
tological lesions studied.
Other disadvantages
Disadvantages are the costs associated with the disposable 
materials of the vacuum suction system, which are 10-15 times 
higher than for 14-gauge automated-needle biopsy. Further-
more, VABB for a malignant lesion may lead to difficulties es-
timating the true size of the tumor at excision, when most of the 
lesion has been sampled at vacuum biopsy, which is an impor-
tant indicator for adjuvant therapy
COMPLICATIONS
Complications of this procedure may include subcutaneous 
bleeding, postoperative hematoma, a skin defect, or pneumo-
thorax. The reported complication rate ranges from 0 to 9% 
with a mean of 2.5%. Hematoma is the most frequent post-pro-
cedure complication [15,28,48,52-54]. Most complications are 
mild to moderate in severity.
However, Simon et al. [52] reported five patients in whom 
bleeding could not be controlled by the normal 10 minutes of 
post-procedural compression, and one patient in whom a vaso-
vagal response occurred. In four of the five patients, hemostasis 
was achieved with additional compression for no more than 
20 minutes. In one patient, 90 minutes was required to achieve 
hemostasis. Post-procedural bleeding usually requires no spe-
cific intervention other than adequate compression of the pro-
cedural site. Parker et al. [15] reported a 5-mm skin defect that 
resulted from biopsy of a superficial lesion. Perez-Fuentes et 
al. [53] reported a case of post-procedural bleeding that was not 
resolved by compression and required surgical intervention. 
Fine et al. [30] reported two serious adverse events: one pa-
tient who suffered post-procedural bleeding required a second 
procedure to tie off the damaged vessel, and another patient 
who suffered a surgical skin tear requiring skin closure.
Therefore, great care should be taken to avoid a skin tear or 
hematoma during this the VABB procedure. The vacuum sys-
tem coupled with compression by the ultrasound probe may 
lead to a skin tear. To prevent other complications, it is neces-
sary to ensure clear visualization of the needle, use ultrasound 
US at all times, and to provide adequate local anesthesia.
CONCLUSION
VABB is a very reliable sampling technique with very few 
complications. It is relatively easy to use and is well tolerated by 
patients. Because it is less invasive, is easy to use; thus, reduc-
ing the cost of repetitive follow-ups or more expensive addi-
tional examinations. Above all, VABB reduces the time between 
detection and diagnosis, which is very important for patient 
reassurance. VABB also has a prognostic impact, because tu-
mors can be diagnosed at an earlier stage and a delayed diagno-
sis, with a potential medical legal impact, can also be avoided.
In the near future, open surgical biopsies for benign lesions 
will be eliminated at our hospital. In cases of malignancy, a one-
step therapeutic operation will be planned, and the patient will 
be fully informed. Because of the high number of small and in 
situ lesions, breast-conserving surgery and sentinel node pro-
cedures will be performed in the majority of cases. The 8-gauge 
VABB system is highly accurate for a diagnostic biopsy of sus-
picious breast lesions and is highly successful for completely 
removing appropriately selected presumed benign breast le-
sions. Breast surgeons should replace open excision biopsy with 
VABB to initially manage breast lesions.
CONFLICT OF INTEREST
The authors declare that they have no competing interests.
REFERENCES
1.	American	College	of	Radiology.	Breast	imaging	reporting	and	data	sys-
tem	(BI-RADS).	4th	ed.	Reston:	American	College	of	Radiology;	2003.6  Hai-LinPark,etal.
http://ejbc.kr  DOI: 10.4048/jbc.2011.14.1.1
2.	Varas	X,	Leborgne	F,	Leborgne	JH.	Nonpalpable,	probably	benign	le-
sions:	role	of	follow-up	mammography.	Radiology	1992;184:409-14.
3.	Sickles	EA.	Probably	benign	breast	lesions:	when	should	follow-up	be	
recommended	and	what	is	the	optimal	follow-up	protocol?	Radiology	
1999;213:11-4.
4.	Stavros	AT,	Thickman	D,	Rapp	CL,	Dennis	MA,	Parker	SH,	Sisney	GA.	
Solid	breast	nodules:	use	of	sonography	to	distinguish	between	benign	
and	malignant	lesions.	Radiology	1995;196:123-34.
5.	Graf	O,	Helbich	TH,	Fuchsjaeger	MH,	Hopf	G,	Morgun	M,	Graf	C,	et	
al.	Follow-up	of	palpable	circumscribed	noncalcified	solid	breast	mass-
es	at	mammography	and	US:	can	biopsy	be	averted?	Radiology	2004;	
233:850-6.
6.	Houssami	N,	Cheung	MN,	Dixon	JM.	Fibroadenoma	of	the	breast.	
Med	J	Aust	2001;174:185-8.
7.	Stavros	AT.	Ultrasound	of	solid	breast	nodules:	distinguishing	benign	
from	malignant.	In:	Stavros	AT,	editor.	Breast	Ultrasound.	Philadelphia:	
Lippincott	Williams	&	Wilkins;	2004.	p.445-525.
8.	Parker	SH,	Jobe	WE,	Dennis	MA,	Stavros	AT,	Johnson	KK,	Yakes	WF,	
et	al.	US-guided	automated	large-core	breast	biopsy.	Radiology	1993;	
187:507-11.
9.	Liberman	L,	Feng	TL,	Dershaw	DD,	Morris	EA,	Abramson	AF.	US-
guided	core	breast	biopsy:	use	and	cost-effectiveness.	Radiology	1998;	
208:717-23.
10.	Smith	DN,	Rosenfield	Darling	ML,	Meyer	JE,	Denison	CM,	Rose	DI,	
Lester	S,	et	al.	The	utility	of	ultrasonographically	guided	large-core	nee-
dle	biopsy:	results	from	500	consecutive	breast	biopsies.	J	Ultrasound	
Med	2001;20:43-9.
11.	Pisano	ED,	Fajardo	LL,	Tsimikas	J,	Sneige	N,	Frable	WJ,	Gatsonis	CA,	et	
al.	Rate	of	insufficient	samples	for	fine-needle	aspiration	for	nonpalpa-
ble	breast	lesions	in	a	multicenter	clinical	trial:	The	Radiologic	Diagnos-
tic	Oncology	Group	5	Study.	The	RDOG5	investigators.	Cancer	1998;	
82:679-88.
12.	Chaiwun	B,	Settakorn	J,	Ya-In	C,	Wisedmongkol	W,	Rangdaeng	S,	
Thorner	P.	Effectiveness	of	fine-needle	aspiration	cytology	of	breast:	
analysis	of	2,375	cases	from	northern	Thailand.	Diagn	Cytopathol	2002;	
26:201-5.
13.	Burbank	F,	Parker	SH.	Methods	for	evaluating	the	quality	of	an	image-
guided	breast	biopsy	program.	Semin	Breast	Dis	1998;1:71-83.
14.	Parker	SH,	Dennis	MA,	Stavros	AT,	Johnson	KK.	Ultrasound-guided	
mamtmeotomoy:	a	new	breast	biopsy	technique.	J	Diagn	Med	Sonogr	
1996;12:113-8.
15.	Parker	SH,	Klaus	AJ,	McWey	PJ,	Schilling	KJ,	Cupples	TE,	Duchesne	N,	
et	al.	Sonographically	guided	directional	vacuum-assisted	breast	biopsy	
using	a	handheld	device.	AJR	Am	J	Roentgenol	2001;177:405-8.
16.	Grady	I,	Gorsuch	H,	Wilburn-Bailey	S.	Ultrasound-guided,	vacuum-
assisted,	percutaneous	excision	of	breast	lesions:	an	accurate	technique	
in	the	diagnosis	of	atypical	ductal	hyperplasia.	J	Am	Coll	Surg	2005;201:	
14-7.
17.	Burbank	F.	Stereotactic	breast	biopsy:	comparison	of	14-	and	11-gauge	
Mammotome	probe	performance	and	complication	rates.	Am	Surg	
1997;63:988-95.
18.	Jackman	RJ,	Marzoni	FA	Jr,	Rosenberg	J.	False-negative	diagnoses	at	
stereotactic	vacuum-assisted	needle	breast	biopsy:	long-term	follow-up	
of	1,280	lesions	and	review	of	the	literature.	AJR	Am	J	Roentgenol	2009;	
192:341-51.
19.	Jackman	RJ,	Birdwell	RL,	Ikeda	DM.	Atypical	ductal	hyperplasia:	can	
some	lesions	be	defined	as	probably	benign	after	stereotactic	11-gauge	
vacuum-assisted	biopsy,	eliminating	the	recommendation	for	surgical	
excision?	Radiology	2002;224:548-54.
20.	Baez	E,	Huber	A,	Vetter	M,	Hackelöer	BJ.	Minimal	invasive	complete	
excision	of	benign	breast	tumors	using	a	three-dimensional	ultrasound-
guided	mammotome	vacuum	device.	Ultrasound	Obstet	Gynecol	2003;	
21:267-72.
21.	Zografos	GC,	Zagouri	F,	Sergentanis	TN,	Nonni	A,	Michalopoulos	NV,	
Kontogianni	P,	et	al.	Diagnosing	papillary	lesions	using	vacuum-assist-
ed	breast	biopsy:	should	conservative	or	surgical	management	follow?	
Onkologie	2008;31:653-6.
22.	Park	HL,	Chang	SY,	Huh	JY,	Kim	JY.	Is	further	diagnostic	surgery	neces-
sary	for	the	benign	papillary	lesions	that	are	diagnosed	by	large	volume	
vacuum	assisted	breast	biopsy?	J	Breast	Cancer	2010;13:206-11.
23.	Johnson	AT,	Henry-Tillman	RS,	Smith	LF,	Harshfield	D,	Korourian	S,	
Brown	H,	et	al.	Percutaneous	excisional	breast	biopsy.	Am	J	Surg	2002;	
184:550-4.
24.	Sperber	F,	Blank	A,	Metser	U,	Flusser	G,	Klausner	JM,	Lev-Chelouche	D.	
Diagnosis	and	treatment	of	breast	fibroadenomas	by	ultrasound-guid-
ed	vacuum-assisted	biopsy.	Arch	Surg	2003;138:796-800.
25.	Park	HL,	Kwak	JY,	Lee	SH,	Kim	JY,	Kim	KI,	Kim	WW,	et	al.	Excision	of	
benign	breast	disease	by	ultrasound-guided	vacuum	assisted	biopsy	
device	(Mammotome).	J	Korean	Surg	Soc	2005;68:96-101.
26.	Park	HL,	Kwak	JY,	Jung	H,	Lee	SH,	Shim	JY,	Kim	JY,	et	al.	Is	mammo-
tome	excision	feasible	for	benign	breast	mass	bigger	than	3	cm	in	great-
est	dimension?	J	Korean	Surg	Soc	2006;70:25-9.
27.	Park	HL,	Kwak	JY,	Lee	SH,	Jung	HK,	Kim	JY,	Shim	JY,	et	al.	Excision	of	
benign	breast	tumor	by	an	ultrasound-guided	hand	held	Mammotome	
biopsy	device.	J	Breast	Cancer	2005;8(3):92-8.
28.	Tagaya	N,	Nakagawa	A,	Ishikawa	Y,	Oyama	T,	Kubota	K.	Experience	
with	ultrasonographically	guided	vacuum-assisted	resection	of	benign	
breast	tumors.	Clin	Radiol	2008;63:396-400.
29.	Fine	RE,	Israel	PZ,	Walker	LC,	Corgan	KR,	Greenwald	LV,	Berenson	JE,	
et	al.	A	prospective	study	of	the	removal	rate	of	imaged	breast	lesions	by	
an	11-gauge	vacuum-assisted	biopsy	probe	system.	Am	J	Surg	2001;	
182:335-40.
30.	Fine	RE,	Boyd	BA,	Whitworth	PW,	Kim	JA,	Harness	JK,	Burak	WE.	
Percutaneous	removal	of	benign	breast	masses	using	a	vacuum-assisted	
hand-held	device	with	ultrasound	guidance.	Am	J	Surg	2002;184:332-6.
31.	Govindarajulu	S,	Narreddy	S,	Shere	MH,	Ibrahim	NB,	Sahu	AK,	Caw-
thorn	SJ.	Preoperative	mammotome	biopsy	of	ducts	beneath	the	nipple	
areola	complex.	Eur	J	Surg	Oncol	2006;32:410-2.
32.	Brown	TA,	Wall	JW,	Christensen	ED,	Smith	DV,	Holt	CA,	Carter	PL,	et	
al.	Atypical	hyperplasia	in	the	era	of	stereotactic	core	needle	biopsy.	J	
Surg	Oncol	1998;67:168-73.
33.	Gadzala	DE,	Cederbom	GJ,	Bolton	JS,	McKinnon	WM,	Farr	GH	Jr,	
Champaign	J,	et	al.	Appropriate	management	of	atypical	ductal	hyper-
plasia	diagnosed	by	stereotactic	core	needle	breast	biopsy.	Ann	Surg	
Oncol	1997;4:283-6.
34.	Jackman	RJ,	Nowels	KW,	Shepard	MJ,	Finkelstein	SI,	Marzoni	FA	Jr.	
Stereotaxic	large-core	needle	biopsy	of	450	nonpalpable	breast	lesions	
with	surgical	correlation	in	lesions	with	cancer	or	atypical	hyperplasia.	
Radiology	1994;193:91-5.
35.	Liberman	L,	Smolkin	JH,	Dershaw	DD,	Morris	EA,	Abramson	AF,	TheCurrentRoleofVacuumAssistedBreastBiopsySysteminBreastDisease 7
DOI: 10.4048/jbc.2011.14.1.1  http://ejbc.kr
Rosen	PP.	Calcification	retrieval	at	stereotactic,	11-gauge,	directional,	
vacuum-assisted	breast	biopsy.	Radiology	1998;208:251-60.
36.	Jackman	RJ,	Burbank	F,	Parker	SH,	Evans	WP	3rd,	Lechner	MC,	Rich-
ardson	TR,	et	al.	Atypical	ductal	hyperplasia	diagnosed	at	stereotactic	
breast	biopsy:	improved	reliability	with	14-gauge,	directional,	vacuum-
assisted	biopsy.	Radiology	1997;204:485-8.
37.	Jackman	RJ,	Burbank	F,	Parker	SH.	Atypical	ductal	hyperplasia	diag-
nosed	by	11-gauge,	directional,	vacuum-assisted	breast	biopsy:	how	of-
ten	is	carcinoma	found	at	surgery?	[abstract].	Radiology	1997;205:A325.
38.	Liberman	L,	Hann	LE,	Dershaw	DD,	Morris	EA,	Abramson	AF,	Rosen	
PP.	Mammographic	findings	after	stereotactic	14-gauge	vacuum	biopsy.	
Radiology	1997;203:343-7.
39.	Burbank	F.	Mammographic	findings	after	14-gauge	automated	needle	
and	14-gauge	directional,	vacuum-assisted	stereotactic	breast	biopsies.	
Radiology	1997;204:153-6.
40.	Diaz	LK,	Wiley	EL,	Venta	LA.	Are	malignant	cells	displaced	by	large-
gauge	needle	core	biopsy	of	the	breast?	AJR	Am	J	Roentgenol	1999;173:	
1303-13.
41.	Liberman	L,	Vuolo	M,	Dershaw	DD,	Morris	EA,	Abramson	AF,	La-
Trenta	LR,	et	al.	Epithelial	displacement	after	stereotactic	11-gauge	di-
rectional	vacuum-assisted	breast	biopsy.	AJR	Am	J	Roentgenol	1999;	
172:677-81.
42.	Liberman	L,	Dershaw	DD,	Rosen	PP,	Abramson	AF,	Deutch	BM,	Hann	
LE.	Stereotaxic	14-gauge	breast	biopsy:	how	many	core	biopsy	speci-
mens	are	needed?	Radiology	1994;192:793-5.
43.	Parker	SH,	Burbank	F.	A	practical	approach	to	minimally	invasive	breast	
biopsy.	Radiology	1996;200:11-20.
44.	Parker	SH,	Klaus	AJ.	Performing	a	breast	biopsy	with	a	directional,	vac-
uum-assisted	biopsy	instrument.	Radiographics	1997;17:1233-52.
45.	Berg	JW,	Robbins	GF.	A	late	look	at	the	safety	of	aspiration	biopsy.	Can-
cer	1962;15:826-7.
46.	Robbins	GF,	Brothers	JH	3rd,	Eberhart	WF,	Quan	S.	Is	aspiration	biop-
sy	of	breast	cancer	dangerous	to	the	patient?	Cancer	1954;7:774-8.
47.	Krainick-Strobel	U,	Huber	B,	Majer	I,	Bergmann	A,	Gall	C,	Gruber	I,	et	
al.	Complete	extirpation	of	benign	breast	lesions	with	an	ultrasound-
guided	vacuum	biopsy	system.	Ultrasound	Obstet	Gynecol	2007;29:	
342-6.
48.	Fine	RE,	Whitworth	PW,	Kim	JA,	Harness	JK,	Boyd	BA,	Burak	WE	Jr.	
Low-risk	palpable	breast	masses	removed	using	a	vacuum-assisted	
hand-held	device.	Am	J	Surg	2003;186:362-7.
49.	Jackman	RJ,	Marzoni	FA	Jr,	Nowels	KW.	Percutaneous	removal	of	be-
nign	mammographic	lesions:	comparison	of	automated	large-core	and	
directional	vacuum-assisted	stereotactic	biopsy	techniques.	AJR	Am	J	
Roentgenol	1998;171:1325-30.
50.	March	DE,	Coughlin	BF,	Barham	RB,	Goulart	RA,	Klein	SV,	Bur	ME,	et	
al.	Breast	masses:	removal	of	all	US	evidence	during	biopsy	by	using	a	
handheld	vacuum-assisted	device--initial	experience.	Radiology	2003;	
227:549-55.
51.	Vargas	HI,	Vargas	MP,	Gonzalez	K,	Burla	M,	Khalkhali	I.	Percutaneous	
excisional	biopsy	of	palpable	breast	masses	under	ultrasound	visualiza-
tion.	Breast	J	2006;12(5	Suppl	2):S218-22.
52.	Simon	JR,	Kalbhen	CL,	Cooper	RA,	Flisak	ME.	Accuracy	and	compli-
cation	rates	of	US-guided	vacuum-assisted	core	breast	biopsy:	initial	re-
sults.	Radiology	2000;215:694-7.
53.	Perez-Fuentes	JA,	Longobardi	IR,	Acosta	VF,	Marin	CE,	Liberman	L.	
Sonographically	guided	directional	vacuum-assisted	breast	biopsy:	pre-
liminary	experience	in	Venezuela.	AJR	Am	J	Roentgenol	2001;177:	
1459-63.
54.	Chen	SC,	Yang	HR,	Hwang	TL,	Chen	MF,	Cheung	YC,	Hsueh	S.	Intra-
operative	ultrasonographically	guided	excisional	biopsy	or	vacuum-as-
sisted	core	needle	biopsy	for	nonpalpable	breast	lesions.	Ann	Surg	2003;	
238:738-42.